kempharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (nces) to treat serious medical conditions through its proprietary and broadly applicable ligand activated therapy (lat) approach. the company utilizes its lat technology to generate improved prodrug versions of fda approved drugs in the high needs areas of pain, adhd and other cns diseases.
Company profile
Ticker
ZVRA
Exchange
Website
CEO
Travis Mickle
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
KEMPHARM INC, KEMPHARM, INC
SEC CIK
Corporate docs
Subsidiaries
Acer Therapeutics Inc. ...
ZVRA stock data
Latest filings (excl ownership)
424B3
Prospectus supplement
10 Apr 24
8-K
Entry into a Material Definitive Agreement
10 Apr 24
EFFECT
Notice of effectiveness
9 Apr 24
S-3/A
Shelf registration (amended)
5 Apr 24
DEFA14A
Additional proxy soliciting materials
3 Apr 24
DEF 14A
Definitive proxy
3 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
28 Mar 24
8-K
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of
26 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
Transcripts
ZVRA
Earnings call transcript
2023 Q4
28 Mar 24
ZVRA
Earnings call transcript
2023 Q3
7 Nov 23
ZVRA
Earnings call transcript
2023 Q2
14 Aug 23
ZVRA
Earnings call transcript
2023 Q1
15 May 23
ZVRA
Earnings call transcript
2022 Q4
7 Mar 23
ZVRA
Earnings call transcript
2022 Q3
10 Nov 22
ZVRA
Earnings call transcript
2022 Q3
9 Nov 22
ZVRA
Earnings call transcript
2022 Q2
11 Aug 22
ZVRA
Earnings call transcript
2022 Q2
11 Aug 22
ZVRA
Earnings call transcript
2022 Q1
13 May 22
Latest ownership filings
SC 13G
Nantahala Capital Management, LLC
14 Feb 24
4
Joshua Schafer
2 Feb 24
4
Timothy J. Sangiovanni
2 Feb 24
4
Christal M M Mickle
2 Feb 24
4
Sven Guenther
2 Feb 24
4
R. LaDuane Clifton
2 Feb 24
4
Neil F. McFarlane
2 Feb 24
4
Alvin Shih
2 Feb 24
3
Alvin Shih
2 Feb 24
SC 13G
BlackRock Inc.
29 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 43.27 mm | 43.27 mm | 43.27 mm | 43.27 mm | 43.27 mm | 43.27 mm |
Cash burn (monthly) | 7.64 mm | 2.23 mm | 5.12 mm | 3.68 mm | 1.54 mm | 1.82 mm |
Cash used (since last report) | 52.68 mm | 15.39 mm | 35.30 mm | 25.38 mm | 10.63 mm | 12.55 mm |
Cash remaining | -9.41 mm | 27.88 mm | 7.97 mm | 17.89 mm | 32.64 mm | 30.72 mm |
Runway (months of cash) | -1.2 | 12.5 | 1.6 | 4.9 | 21.2 | 16.9 |
Institutional ownership, Q3 2023
27.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 81 |
Opened positions | 14 |
Closed positions | 6 |
Increased positions | 25 |
Reduced positions | 16 |
13F shares | Current |
---|---|
Total value | 55.85 bn |
Total shares | 11.73 mm |
Total puts | 141.00 k |
Total calls | 129.40 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Nantahala Capital Management | 2.31 mm | $11.13 bn |
BLK Blackrock | 2.15 mm | $10.37 bn |
Vanguard | 1.61 mm | $7.77 bn |
Geode Capital Management | 679.05 k | $3.27 bn |
Janney Montgomery Scott | 674.37 k | $3.25 mm |
STT State Street | 628.23 k | $3.03 bn |
Auctus Fund | 450.00 k | $4.25 mm |
Retirement Planning Co of New England | 347.40 k | $1.67 bn |
Braun Samuel J | 323.50 k | $2.83 mm |
NTRS Northern Trust | 270.44 k | $1.30 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Jan 24 | Sangiovanni Timothy J. | RSU Common Stock | Grant | Acquire A | No | No | 0 | 35,000 | 0.00 | 35,000 |
31 Jan 24 | Christal M M Mickle | RSU Common Stock | Grant | Acquire A | No | No | 0 | 77,000 | 0.00 | 77,000 |
31 Jan 24 | Sven Guenther | RSU Common Stock | Grant | Acquire A | No | No | 0 | 79,000 | 0.00 | 79,000 |
31 Jan 24 | Clifton R. LaDuane | RSU Common Stock | Grant | Acquire A | No | No | 0 | 130,000 | 0.00 | 130,000 |
31 Jan 24 | McFarlane Neil F. | RSU Common Stock | Grant | Acquire A | No | No | 0 | 700,000 | 0.00 | 700,000 |
News
Zevra Therapeutics Presents New Data On Long-Term Safety And Efficacy Of Arimoclomol As Treatment For Niemann-Pick Disease Type C At SIMD 45th Annual Meeting
15 Apr 24
HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $15 Price Target
3 Apr 24
Zevra Therapeutics: Q4 Earnings Insights
28 Mar 24
Zevra Therapeutics Q4 2023 GAAP EPS $(0.40) Misses $(0.27) Estimate, Sales $13.217M Beat $11.738M Estimate
28 Mar 24
Earnings Scheduled For March 28, 2024
28 Mar 24
Press releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
24 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
20 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
16 Apr 24
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
15 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
12 Apr 24